PhotoCure ASA (PhotoCure ASA) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is PhotoCure ASA Debt-to-Equity?

PhotoCure ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. PhotoCure ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. PhotoCure ASA's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $45.52 Mil. PhotoCure ASA's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PhotoCure ASA's Debt-to-Equity or its related term are showing as below:

PHCUF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.05 Max: 0.15
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of PhotoCure ASA was 0.15. The lowest was 0.01. And the median was 0.05.

PHCUF's Debt-to-Equity is ranked better than
84.32% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs PHCUF: 0.04

PhotoCure ASA Debt-to-Equity Historical Data

The historical data trend for PhotoCure ASA's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhotoCure ASA Debt-to-Equity Chart

PhotoCure ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.11

0.15

0.11

0.04

PhotoCure ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	-	-	0.04	-

Competitive Comparison of PhotoCure ASA's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhotoCure ASA's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PhotoCure ASA's Debt-to-Equity falls into.

PhotoCure ASA Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PhotoCure ASA's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.532	+	1.325)	/	45.77
	=	0.04

PhotoCure ASA's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	45.523
	=	0.00

PhotoCure ASA (OTCPK:PHCUF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PhotoCure ASA Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PhotoCure ASA's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PhotoCure ASA (PhotoCure ASA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PhotoCure ASA (OTCPK:PHCUF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PHOO:Sweden PHO:Norway

Address

Hoffsveien 4, Oslo, NOR, 0275

Website

https://www.photocure.com

PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products specialty pharmaceutical companies. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. It has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, Netherlands, Other European countries, and the United States.